Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;11(4):1451-1469.
doi: 10.1007/s40122-022-00437-2. Epub 2022 Oct 12.

Efficacy and Safety of Pregabalin Prolonged Release-Etoricoxib Combination Compared to Etoricoxib for Chronic Low Back Pain: Phase 3, Randomized Study

Amit B Yeole  1 , G Sree Ranga Lakshmi  2 , C J Selvakumar  3 , Vijay G Goni  4 , C L Nawal  5 , Bhanoth J Valya  6 , Brijesh J Patel  7 , Rohit D Patel  8 , Eknath D Pawar  9 , Ranajit Panigrahi  10 , Ashish Y Kumar  11 , Shrinivas S Shintre  12 , Prashant H Devkare  13 , Shruti K Dharmadhikari  14 , Sanjay Y Choudhari  15 , Maulik S Doshi  16 , Suyog C Mehta  14 , Sadhna J Joglekar  13
Affiliations

Efficacy and Safety of Pregabalin Prolonged Release-Etoricoxib Combination Compared to Etoricoxib for Chronic Low Back Pain: Phase 3, Randomized Study

Amit B Yeole et al. Pain Ther. 2022 Dec.

Abstract

Introduction: Currently available treatments for chronic lower back pain (CLBP) do not adequately address both nociceptive and neuropathic components of pain. We evaluated efficacy and safety of fixed-dose combination (FDC) of low-dose pregabalin prolonged release 75 mg-etoricoxib 60 mg to address both pain components.

Methods: This randomized phase 3 trial conducted at 12 centres across India evaluated efficacy (based on mean change in numeric rating scale [NRS], Roland-Morris disability questionnaire [RDQ], visual analogue scale [VAS], patient global impression of improvement [PGI-I], clinical global impression of improvement [CGI-I] and rescue medication consumption) and safety of FDC in comparison to etoricoxib alone in adult patients with CLBP. Treatment duration was 8 weeks.

Results: Of the 371 patients screened, 319 were randomized and considered for efficacy and safety analysis. Both treatment groups had no significant difference in terms of demography and baseline disease characteristics. Significantly better outcomes with FDC compared to etoricoxib were observed at week 4 onwards. At week 8, both groups showed significant reduction in mean NRS score from baseline (- 4.00 ± 1.65 in FDC; - 2.92 ± 1.59 in etoricoxib) with mean NRS score being significantly less in the FDC group compared to etoricoxib group (3.26 ± 1.56 vs 4.31 ± 1.56; p < 0.0001). The FDC was more effective than etoricoxib in terms of significantly greater reduction in RDQ score (- 9.28 ± 4.48 vs - 6.78 ± 4.34; p < 0.0001) and VAS score (- 37.66 ± 18.7 vs - 28.50 ± 16.31; p < 0.0001) at week 8. The FDC was also better in terms of significantly more patients reporting their condition as 'very much better' (36.9% vs 5.0%; p < 0.0001) and clinicians reporting patient's condition as 'very much improved' (36.3% vs 5.7%; p < 0.0001). Overall, study medications were well tolerated.

Conclusion: FDC of pregabalin and etoricoxib provided significant benefits in reducing pain and improving functional status compared with etoricoxib alone in patients with CLBP. Pregabalin prolonged release-etoricoxib FDC could be one of the treatment options for early and sustained pain relief and improvement in quality-of-life in treating CLBP as it addresses both neuropathic and nociceptive components of pain.

Trial registration: CTRI/2018/10/015886.

Keywords: Back pain; Drug combination; Etoricoxib; Neuropathic pain; Pregabalin.

Plain language summary

Low back pain is one of the most common causes of loss of productivity worldwide. About 60% of Indians suffer from low back pain at some point. Low back pain that persists for more than 3 months is classified as chronic low back pain which mostly includes both nociceptive and neuropathic components. Monotherapies, if prescribed, are not completely effective, as they generally only target either nociceptive or neuropathic components of pain. Multiple drugs are usually needed at multiple times a day, at higher doses for optimal effectiveness, and in most cases they have significant side effects if taken over prolonged periods and also add to the pill burden. To minimize treatment-associated adverse effects, and to increase treatment compliance, while addressing both the components of pain, we developed a fixed-dose combination of low-dose pregabalin prolonged release and etoricoxib. A phase 3 trial was designed to assess the efficacy and safety of the fixed-dose combination in comparison with etoricoxib alone in treating chronic low back pain. The combination demonstrated statistically and clinically significant improvement in patient-reported outcomes—pain, functionality and quality of life—as early as 4 weeks after starting the medication. No severe or serious adverse effects were reported. Thus, the combination of low-dose pregabalin prolonged release and etoricoxib could provide an option for optimal management of chronic low back pain. This would provide multiple benefits, such as addressing both nociceptive and neuropathic components of chronic low back pain, reducing drug-related adverse effects because of low dose, reducing pill burden and thereby increasing drug compliance.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
FDC formulation design
Fig. 2
Fig. 2
Bilayer tablet: from oral administration to after contact with gastric fluids
Fig. 3
Fig. 3
Study design
Fig. 4
Fig. 4
Patient disposition
Fig. 5
Fig. 5
Mean change in NRS from enrolment to week 8
Fig. 6
Fig. 6
Mean change in RDQ from enrolment to week 8
Fig. 7
Fig. 7
Mean change in VAS from enrolment to week 8
Fig. 8
Fig. 8
PGI-I at week 4
Fig. 9
Fig. 9
PGI-I at week 8
Fig. 10
Fig. 10
CGI-I at week 4
Fig. 11
Fig. 11
CGI-I at week 8
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Taguchi T, Igarashi A, Watt S, et al. Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): a non-interventional study in Japan. J Pain Res. 2015;8:487–497. - PMC - PubMed
    1. Baron R, Binder A, Attal N, Casale R, Dickenson AH, Treede RD. Neuropathic low back pain in clinical practice. Eur J Pain. 2016;20(6):861–873. doi: 10.1002/ejp.838. - DOI - PMC - PubMed
    1. Koley S, Sandhu NK. An association of body composition components with the menopausal status of patients with low back pain in Tarn Taran, Punjab, India. J Life Sci. 2009;1(2):129–132. doi: 10.1080/09751270.2009.11885144. - DOI
    1. Wu A, March L, Zheng X, et al. Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. Ann Transl Med. 2020;8(6):299. doi: 10.21037/atm.2020.02.175. - DOI - PMC - PubMed
    1. Delitto A, Patterson CG, Stevans JM, et al. Stratified care to prevent chronic low back pain in high-risk patients: the TARGET trial. A multi-site pragmatic cluster randomized trial. EClinicalMedicine. 2021;34:100795. doi: 10.1016/j.eclinm.2021.100795. - DOI - PMC - PubMed

LinkOut - more resources